Coldstream Capital Management Inc. cut its position in Bristol-Myers Squibb Co (NYSE:BMY) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,791 shares of the biopharmaceutical company’s stock after selling 364 shares during the period. Coldstream Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $561,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. Actinver Wealth Management Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $879,000. Aspire Private Capital LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $160,000. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,678,000. Delphi Management Inc. MA acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,371,000. Finally, Bell & Brown Wealth Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 4.5% during the fourth quarter. Bell & Brown Wealth Advisors LLC now owns 29,782 shares of the biopharmaceutical company’s stock worth $1,548,000 after purchasing an additional 1,278 shares in the last quarter. Hedge funds and other institutional investors own 74.28% of the company’s stock.
BMY opened at $46.02 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market cap of $75.98 billion, a P/E ratio of 11.56, a price-to-earnings-growth ratio of 2.39 and a beta of 0.79. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. The business had revenue of $5.97 billion during the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. Bristol-Myers Squibb’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.68 earnings per share. On average, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
A number of brokerages have recently issued reports on BMY. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, April 8th. ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 20th. Bank of America reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 19th. Finally, Credit Suisse Group reiterated a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $59.13.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/04/17/bristol-myers-squibb-co-bmy-holdings-reduced-by-coldstream-capital-management-inc.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: 12b-1 Fees
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.